CLIN Stock Overview
Clean Earth Acquisitions Corp. does not have significant operations. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Clean Earth Acquisitions Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.00 |
52 Week High | US$11.36 |
52 Week Low | US$4.54 |
Beta | 0 |
11 Month Change | -52.96% |
3 Month Change | -52.70% |
1 Year Change | -50.30% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -49.19% |
Recent News & Updates
Recent updates
Shareholder Returns
CLIN | US Capital Markets | US Market | |
---|---|---|---|
7D | -16.8% | 3.0% | 2.2% |
1Y | -50.3% | 57.6% | 31.6% |
Return vs Industry: CLIN underperformed the US Capital Markets industry which returned 20.6% over the past year.
Return vs Market: CLIN underperformed the US Market which returned 23.4% over the past year.
Price Volatility
CLIN volatility | |
---|---|
CLIN Average Weekly Movement | 17.1% |
Capital Markets Industry Average Movement | 3.9% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CLIN's share price has been volatile over the past 3 months.
Volatility Over Time: CLIN's weekly volatility has increased from 9% to 17% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2021 | n/a | Aaron Ratner | cleanearthacquisitions.com |
Clean Earth Acquisitions Corp. does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It focuses on acquiring companies in the clean energy ecosystem, including carbon, hydrogen, sustainable agriculture, and renewable energy.
Clean Earth Acquisitions Corp. Fundamentals Summary
CLIN fundamental statistics | |
---|---|
Market cap | US$83.52m |
Earnings (TTM) | US$4.16m |
Revenue (TTM) | n/a |
20.1x
P/E Ratio0.0x
P/S RatioIs CLIN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CLIN income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | -US$4.16m |
Earnings | US$4.16m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.25 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -36.5% |
How did CLIN perform over the long term?
See historical performance and comparison